COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients

Abstract

Since the beginning of 2020, the whole world has been struggling with the pandemic of Coronavirus Disease 2019 (COVID-19) caused by a novel coronavirus SARS-CoV-2. The SARS-CoV-2 infection depends on ACE2, TMPRSS2, and CD147, which are expressed on host cells. Several studies suggest that some single nucleotide polymorphisms (SNPs) of ACE2 might be a risk factor of COVID-19 infection. Genotypes affect ACE2 structure, its serum concentration, and levels of circulating angiotensin (1-7). Moreover, there is evidence that ACE genotype affects the outcomes of acute respiratory distress syndrome (ARDS) treatment, the most severe consequence of SARS-CoV-2 infection. COVID-19 morbidity, infection course, and mortality might depend on ACE D allele frequency. The aim of this narrative review was to analyze and identify the mechanisms of ACE-I and ARBs with particular emphasis on angiotensin receptors and their polymorphism in the light of COVID-19 pandemic as these medications are commonly prescribed to elderly patients. There is no direct evidence yet for ACE-I or ARBs in the treatment of COVID-19. However, for those already taking these medications, both the European Society of Cardiology and the American College of Cardiology recommend continuing the treatment, because at present, there is no clear clinical or scientific evidence to justify the discontinuation of ACE-I or ARBs. Individualized treatment decisions should be based on the clinical condition and co-morbidities of each patient.

Keywords:

• SARI
• hypertension
• coronavirus
• age
• ACEI
• ARB

Introduction

Since the beginning of the year 2020, the whole world has been struggling with the epidemic of the new SARS-CoV-2 virus causing Coronavirus Disease 2019 (COVID-19). It was first detected in the Chinese province of Hubei at the end of 2019, and in March 2020 the World Health Organization (WHO) recognized COVID-19 as a global health threat by declaring it a global pandemic.¹

SARS-CoV-2 is a novel virus from the Coronaviridae family, mainly found as a pathogen in animals (birds and mammals).^1,2 History has already seen human infections with other viruses from this family.^3,4 Both SARS-CoV-1 causing Severe Acute Respiratory Syndrome (SARS) and MERS-CoV causing Middle East Respiratory Syndrome (MERS) show similarity to SARS-CoV-2 causing COVID-19 by using receptors for Angiotensin II (AngII) for viral entry into the cell during infection. These receptors are found throughout the human body, with large numbers occurring in the lungs, especially on type 2 pneumocytes, which explains why the symptoms are mainly associated with the respiratory system.^3,4

The main source of infection spread is droplet and direct contact, but fecal-oral route and direct intraneural entry through olfactory nerves have been suggested.^5–7 Usually, the SARS-CoV-2 infection is asymptomatic, while symptoms include fever, weakness, myalgia, cough, difficulty breathing, sometimes abdominal discomfort and diarrhea or anosmia.⁶–,⁸ It has also been suggested that neurological presentation, including delirium, may precede respiratory symptoms.^9,10 It is important to identify laboratory abnormalities associated with COVID-19, including leuko- and lymphopenia, thrombocytopenia, elevated lactate dehydrogenase level, increased liver enzymes or d-dimers.^11,12 People with symptoms often develop rapidly progressing infections of the lower respiratory tract, which can lead to viral pneumonia and Severe Acute Respiratory Infection (SARI), as well as sepsis and death.^8,13

The aim of this narrative review was to analyze and identify the mechanisms of ACE-I and ARBs with particular emphasis on angiotensin receptors and their polymorphism in the light of COVID-19 pandemic as these medications are commonly prescribed to elderly patients. The selected literature review is based on an in-depth analysis and selection of articles in terms of their credibility and relevance to the topic. This is only a small part of the available literature on the topic, but we chose the most reliable individual articles for the purpose of this review.

Connection Between RAS Activity, Age and COVID-19 Epidemiology

In estimating the course of the disease, the most common patient profile is important. The current meta-analyzes determine the average age of the patient to be between 30 and 79 years of age.¹³

Concomitant diseases and multimorbidity are serious problems of modern times. One of the main civilization diseases is hypertension.¹⁴ The possibility of a coexistence of hypertension and susceptibility for SARS-CoV-2 infection raises many questions; therefore, it is important to know the pathogenesis and mechanisms of both diseases. We chose several, most recent articles describing these mechanisms.

Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients.¹³ In a study on a rat model in 12-day treatment with drugs that either inhibit the synthesis of circulating Ang II or block the AT1 receptor, the therapy induced an increase in ACE2 heart mRNA, accompanied by an increase in ACE2 activity in the heart membrane of rats treated with any of losartan or both losartan and lisinopril. Although the dominant effect of ACE inhibition may be due to the combined effect of reduced Ang II formation and Ang 1–7 metabolism (1–7), the antihypertensive effect of AT1 antagonists may be partially due to increased Ang II metabolism by ACE2.¹⁵ The current study confirmed that increased age was associated with death in patients with COVID-19. Previous studies in macaques inoculated with SARS-CoV found that older macaques had stronger host innate responses to virus infection than younger adults, with an increase in differential expression of genes associated with inflammation, whereas expression of type I interferon beta was reduced. The age-dependent defects in T-cell and B-cell function and the excess production of type 2 cytokines could lead to a deficiency in the control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcome.¹⁶ More than half of these people suffer from associated diseases, mainly hypertension - the most common chronic disease in the elderly.^17–19 The most commonly used drug groups in antihypertensive therapy are angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs).²⁰ Due to the mechanism of development of COVID-19 infection, questions arise about the legitimacy of the use of these drugs in the treatment of patients and the risks or therapeutic options associated with it should be identified.

The Role of Renin-Angiotensin System in COVID-19 Infection

It has been proven that SARS-CoV-2 infection depends on ACE2 interaction with the virus (Figure 1). This indicates that the role of the renin-angiotensin (RA) system in the physiology and pathophysiology of the cardiovascular system is of major importance. In the lungs, angiotensin I (ANG I) is being converted to angiotensin II (ANG II). Further, ANG II binds to either AT1 receptor (AT1R) causing vasoconstriction, hypertension, promoting inflammation, and may be converted to angiotensin (ANG IV) via AT4 receptor (AT4R) causing thrombosis. The role of ACE2 is to inactivate ANG II by converting it to angiotensin (1–7) (ANG (1–7)) that binds to Mas receptor causing vasodilation and hypotension. Thus, in a healthy individual, ACE2 negatively regulates the renin-angiotensin (RA) system and attenuates vasoconstriction, fibrosis, and hypertrophy induced by it.²¹

When the spike protein of SARS-CoV-2 binds with ACE2 this leads to the internalization of the complex and further to ACE2 shedding by enzyme ADAM17. In 2005, studies appeared on the effect of Tumor Necrosis Factor-α Convertase (ADAM17) on the penetration of SARS virus into the cells. ADAM17 overexpression has been shown to lead to increased virus penetration.²² Palau et al analyzed data on this metalloproteinase in the context of COVID-19 infection.²³ ADAM17 has been shown to compete with TMPRSS2 for ACE2, which, in light of the reports regarding the effect of TMPRSS2 on viral penetration, forces further research into the mechanisms of viral penetration to prevent infection.^23,24

Decreased availability of ACE2 causes less ANG II degradation. Excessive amounts of ANG II lead not only to overstimulation of AT1R but to conversion to ANG IV which promotes thrombosis via AT4R. This leads to abnormalities seen in COVID-19, namely acute lung injury with local vasoconstriction facilitating ARDS, myocardial injury, and thrombosis.²⁵ The potential effect of ACE-I/ARBs treatment may be seen in upregulation of ACE2, leading to the increased amounts of free ACE2 after viral binding. ACE-Inhibitors (ACE-I) cause less synthesis of ANG II and ARBs prevent ANGII from binding on the AT1R. This leads to less AT1R stimulation and persistent interaction with ACE2, avoiding ACE2 internalization. ACE-2 is available for the transformation of ANGI I into Angiotensin (1–7), causing less AT1R and AT4R stimulation.

Figure 1 The effects of renin-angiotensin system during SARS-CoV-2 infection.

ACE2 Expression and ACE2 Gene Polymorphisms

SARS-CoV-2 infection depends not only on ACE2, but also on TMPRSS2, a cellular protease and CD147 (extracellular matrix metalloproteinase inducer – EMMPRIN) which are expressed on host cells.^24,26-28 ACE2, the homolog of ACE, is composed of a single zinc metalloprotease active site, identical to ACE only in 42%, and a transmembrane domain.^29–31 Its expression is not so unique in organs as ACE. ACE2 transcripts are found in the renal tubular epithelium, testis, type 2 pneumocytes, endothelium of coronary and intrarenal vessels.^29,32,33 ACE2 is present in serum after cleavage of the transmembrane domain.²⁹ This soluble form might limit CoVs infection ^34,35 and if combined with Fc fragment of the antibody, it neutralizes the virus.³⁶ The aforementioned findings suggest that the course of infection might depend on the ACE2 expression.

ACE2 activity is negatively correlated with blood pressure and BMI.³⁷ It is hypothesized that ACE2 activity is a predictor of cardiac dysfunction in patients with hypertension.³⁷ However, Chen et al found that circulating ACE2 levels are positively associated with serum creatinine, a marker of kidney disease.³⁸

ACE2 is located on a short arm of a chromosome X (Xp22.2) and comprises 19 exons.^29,39 Since its identification as a potentially functional for cardiovascular diseases, there have been many trials verifying the hypothetical influence of Single Nucleotide Polymorphisms (SNPs) located within ACE2 gene.³⁹ ACE2 might influence cardiovascular diseases even before birth. A study on 474 samples of umbilical cord blood connected rs2074192 (T allele) with a probability of being born as small for gestational age (SGA) – OR = 22.93 (p<0.05). SGA is associated with cardiovascular diseases in adulthood.⁴⁰

Many ACE2 variants are related to common diseases, whose incidence depends on the balance in the renin-angiotensin-aldosterone pathway, as depicted in Table 1. Hypertension is associated with rs1514283, rs2074192, rs233575, rs4646155, rs4646176, rs2285666, rs879922, rs2106809, rs4646188, rs4240157, rs4830542, rs2158083, and rs879922.^37,41,42 Some of these variants affect the response to ACE inhibitors.^43,44 Moreover, rs2285666 (A allele) is associated with lower probability of cardiovascular death in female population (HR = 0.3, p<0.05).^41,45,46 Amongst people with hypertension minor alleles: rs2106809 and rs2074192 are associated with left ventricular hypertrophy.⁴⁷ Lieb et al found the association between rs4646156, rs879922, rs4240157, rs233575 and higher septal wall thickness or left ventricular hypertrophy in male population.⁴⁸ This association might be a result of lower levels of circulating Angiotensin (1–7) in this group.³⁸ Wang et al conducted a study on 265 with atrial fibrillation (AF) and 289 healthy people. Researchers found that rs2106809 (T allele) is AF risk factor.⁴⁹

Table 1 The Most Important ACE2 SNPs Related to Essential Hypertension

Disease	ACE2 Single Nucleotide Polymorphisms
Essential hypertension	rs1514283, rs2074192, rs233575, rs4646155, rs4646176, rs2285666, rs879922, rs2106809, rs4646188, rs4240157, rs4830542, rs2158083, rs879922
Cardiovascular death	rs2285666
Left ventricular hypertrophy	rs2106809, rs2074192, rs4646156, rs879922, rs4240157, rs233575
Atrial fibrillation	rs2106809
Dyslipidemia	rs1978124, rs2106809, rs233575, rs4646188, rs879922, rs2285666, rs4646142, rs4646155

Abbreviation: ACE2, angiotensin-converting eEnzyme 2.

ACE2 SNPs might influence patients’ lipid profiles. LDL concentration is associated with rs1978124, rs2106809, rs233575, rs4646188, and rs879922. HDL concentration might be decreased in individuals with rs2106809, rs2285666, rs4646142, rs4646155, and rs4646188.⁴¹ SNPs: rs2106809 and rs4646188 are risk factors for hypertriglyceridemia.⁴¹

Some projects failed to find any association between ACE2 variants and diseases, whose frequency is correlated with blood pressure. Wu et al did not find any association between SNPs and recurrent strokes.⁵⁰

The aforementioned results suggest that some SNPs might be a risk factor of COVID-19. Genotypes affect ACE2 structure, its serum concentration, and levels of circulating angiotensin (1–7).^38,51 Moreover, there is evidence that ACE genotype affects the outcomes of acute respiratory distress syndrome (ARDS) treatment. In a prospective study on 84 patients with ARDS and 200 healthy people, ACE polymorphisms were genotyped. Every study participant was Caucasian. Researchers found that being homozygous for ACE D (deletion in intron 16) allele was associated with increased mortality.⁵² Geographic distribution of ACE I (insertion in intron 16) allele was summarized by Saab et al Its frequency increases eastwards and westwards from the Middle East.⁵³ It was proven that ACE2 decrease the risk of lung failure.³³ Nevertheless, Chiu et al did not find any significant association between ACE2 variants and SARS.⁵⁴ Another interesting study by Goulter et al proved the connection between heart failure and ACE2 expression. ACE2 is probably upregulated due to idiopathic dilated cardiomyopathy and ischemic cardiomyopathy.⁵⁵ It needs to be verified if these diseases affect the likelihood of COVID-19.

COVID-19 morbidity, infection course, and mortality might depend on ACE D allele frequency.⁵⁶ Delanghe et al’s findings are unanimous with the role of ACE in CoVs infections.⁵⁷ Stawiski et al performed genomic datasets analysis and identified multiple ACE2 variants, which might affect COVID-19 susceptibility.⁵⁸ However, none of these SNPs is common in the general population. This finding might help in the recognition of people less and more prone to COVID-19.⁵⁸ Cao et al performed a genetic dataset analysis of various populations for polymorphisms in the ACE2 structure. The differences between populations and higher tissue expression of ACE2 in East Asian populations were determined, which may suggest other susceptibility to infection. However, the studies did not show genetic evidence confirming the existence of the ACE2 mutation resistant to coronavirus protein.⁵⁹

Treatment with ACE-I and ARBs During COVID-19 Pandemic

Co-morbid conditions, including hypertension, diabetes, heart disease, and progressive age have been found to contribute to more severe disease in patients with COVID-19. In addition, these patients were more often admitted to the intensive care unit, received mechanical ventilation, or died compared to patients with mild disease.⁶⁰ Due to the fact that in these diseases, groups of drugs that are often used are drugs that have an inhibitory effect on the RAAS system, there are concerns that they may have contributed to some degree of adverse health effects or more severe course of this disease.^16,60

ACE2 is a key enzyme that breaks down Angiotensin II into Angiotensin (1–7), thus reducing its effect on vasoconstriction, sodium retention, water retention, and fibrosis. Although Angiotensin II is the basic substrate for ACE2, this enzyme also degrades Angiotensin I to Angiotensin (1–9) and is involved in the hydrolysis of other peptides.⁶¹ The balance of these vasoactive peptides has a profound effect on organs and systems and is altered by both ACE inhibitors (which block the action of ACE-1) and ARBs (which block the action of angiotensin II on AT1 receptors). Studies of human tissue samples from 15 different organs have been shown to generally express ACE2, including in the heart and kidneys, as well as in major SARS-CoV-2 target cells (and the site of the dominant injury) – follicular epithelial cells.³² In addition, circulating soluble ACE2 levels are relatively low, and the functional role of ACE2 in the lungs appears to be relatively minimal under normal conditions but might be elevated in some specific clinical conditions.⁶²

There are many hypotheses about the pathomechanism and impact of using ACE-I and ARBs. One of them says that ACEI initially inhibits ACE, which leads to a decrease in the level of angiotensin I, resulting in a possible negative feedback loop, which ultimately regulates more of the ACE2 receptor to be able to interact with the available substrate of Angiotensin I.⁶³ This upregulation of the ACE2 receptor causes an increase in SARS-CoV-2 binding sites, which can lead to COVID-19 infection. This can be especially seen in patients with diabetes or hypertension, as they are usually treated with ACE-I or ARB.⁶³ An April 2020 a study including patients hospitalized in the Hubei Province in China found a death rate of 3.7% for hospitalized patients who had hypertension and were on ACE-I or ARBs versus 9.8% for hospitalized patients with hypertension not on such drugs, suggesting that the drugs are not harmful and may help against the coronavirus.⁶⁴

Otherwise, some researchers believe that using ACE-I or ARBs may be beneficial in preventing COVID-19 infection. Li et al proposed that ACE1 inhibition by ACE-I may stimulate negative feedback. Given the lack of Angiotensin II, an increase in ACE2 receptors and a reduction in general inflammation.⁶⁵

Probably the effect on the renin-angiotensin system by both ACE-I and ARBs leads to increased expression of ACE2. Theoretically, this may help alleviate some of the harmful effects of Angiotensin II on the human body. It is believed that the increased level of soluble ACE2 may act as competitive to SARS-CoV-2 and may slow down the penetration of the virus into cells and protect against damage to lung tissue.³⁰ There is some evidence that ACE-I/ARBs may be beneficial in patients with acute lung injury (ALI) or ARDS as a complication after COVID-19 infection. In a meta-analysis of 37 studies, the use of ACE-I and ARBs was associated with a reduced risk of pneumonia and mortality from pneumonia compared to control treatment.⁶⁶

In one randomized, double-blind, placebo-controlled clinical trial in 61 patients, 8 patients randomly received enalapril up to 10 mg intravenously (within 24 hours after a blood pressure regimen) had more days without assisted ventilation (12.3 vs. 8.7 days; P = 0.18) and days spent outside of the intensive care unit (8.9 vs. 4.9 days; P = 0.09) compared to those randomly assigned to placebo. This study has not yet been completed due to the slow registration of patients.⁶⁷

In another Korean retrospective study of 132 patients with ARDS, 9 patients receiving ACE-I/ARBs showed better survival compared to the control group, although other determinants could influence the results.⁶⁸

Sun et al proposed that ACE-I use implies the ACE receptor/Angiotensin II/Angiotensin-1 receptor pathway and thus interferes with the integrity of ACE2/Angiotensin 1–7/Mas (MAS-associated G-protein coupled receptor). ACE2/angiotensin disruption Route 1–7/Mas may lead to a decrease in ACE2 production, reducing the chance of SARS-CoV-2 getting into the cell.⁶⁹

One study to date has looked at the effects of ACE-I and ARB on the COVID-19 population. According to Peng et al among 112 patients, cardiovascular disease led to worse outcomes, with most deaths following fulminant inflammation, lactic acidosis and thrombotic conditions. The use of ACE-I and ARB did not affect morbidity or mortality.⁷⁰

Receptor polymorphisms have been inclining towards genetic research and phenotyping for years. The main reason for consideration is the lack of response to the treatment of hypertension by ACE-I and ARBs. In 2007, Danser et al proposed ACE phenotyping to explain differences in response to ace inhibitors.⁷¹ Since then, there have been studies in which researchers have focused on convertase variants, while there has been little interest in the receptors themselves. Because of the much more important role played by receptors in infection, Sommerstein et al analyzed the impact of ACE-I and ARBs on COVID-19.⁶⁹ Due to many variables such as age, gender and comorbidities, they were unable to determine the effect of these drugs on the development of infection, but they proved that patients using ACE-I had an increase in the number of ACE2 receptors. Therefore, more research is needed because of the popularity of these drugs.⁷² Zhixin Liu et al conducted a large genetic analysis comparing the structure of the virus and receptors in many animals to detect potential carriers of the virus. Animals possessing an ACE receptor with human-like properties may constitute a reservoir other than bats.⁷³

Thanks to such research, we are able to determine where the virus can exist as a potential source of another infection despite the removal of an infectious focus in humans. This type of research, based on the analysis of receptor structure, may be the key to predicting the severity of patient infections, detecting particularly sensitive patients, and maybe even discovering a treatment by preventing the virus from entering the cells.

Population Studies on the Effect of ACE Inhibitors and ARBs in COVID-19

Constant uncertainty, guesswork, and lack of knowledge about the harmfulness of ACE inhibitors and ARBs in patients with COVID-19 contributed to the creation of population analyzes in this group of patients.

Mancia et al conducted a field study on a group of 6272 infected patients, comparing them with 30,759 controls with similar age, gender, and comorbidities. The results showed that patients with the SARS-CoV-2 virus were more likely to take these drugs; however, this was due to worse health and cardiovascular disease. ACE-I and ARBs have not been shown to affect the risk of COVID-19 infection.⁷⁴

Mehra et al analyzed patients from 169 European, Asian, and North American hospitals for mortality and risk factors. The analysis showed that an increased mortality can be observed in patients with chronic obstructive pulmonary disease (OR=2.96), coronary artery disease (OR=2.7), heart failure (OR=2.48), arrhythmia (OR=1,95), age>65 (OR=1.93), and smokers (OR=1.79). There was no statistical significance in increasing the risk of hospital mortality associated with the use of ACE inhibitors (OR=0.33) and ARBs (OR=1.23).⁷⁵

Reynolds et al also assessed the increased risk of drug use. In patients subjected to COVID-19 diagnostics, the relationship between the use of different classes of hypertensive drugs and the occurrence and severity of the disease itself was evaluated. Again, no statistical significance was demonstrated between the use of any group of drugs for hypertension and the onset of the disease and its severity.⁷⁶

There is no direct evidence yet for ACE or ARB inhibitors in the treatment of COVID-19. However, for those patients already taking these medications, the European Society of Cardiology recommends

That doctors and patients continue treatment because there is no clinical or scientific evidence to suggest that ACE-I or ARBs should be discontinued due to COVID-19 infection.⁷⁷

The American College of Cardiology recommends continuing treatment in conditions such as heart failure, hypertension or ischemic heart disease, and that if COVID-19 occurs, “individualized treatment decisions should be made based on the hemodynamic condition and clinical presentation of each patient”.⁷⁸

According to ClinicalTrials.gov webpage, there are currently 26 clinical trials regarding drugs targeting RAS in COVID-19 (summarized in Table 2), e.g.: NCT4312009, NCT4335786, which aim to verify the effects of initiation of the treatment with drugs interfering with RAS in patients with COVID-19 and NCT4338009, NCT4364893, which verify outcomes of discontinuation of ACE-I/ARBs therapy.⁷⁹ NCT4359953 aims to include 1600 participants and the results are expected in December 2020. This trial is designed to compare one of the ARBs – telmisartan with Hydroxychloroquine and Azithromycin in COVID-19 treatment.⁸⁰

Table 2 Interventional Clinical Trials Verifying the Influence of RAS Blocking on Course and Outcomes of COVID-19

Clinical Trial ID	Number of Participants	Intervention in Experimental Groups	Estimated Study Completion Date
NCT4343001	10,000	Aspirin vs Losartan vs Simvastatin	2021–08
NCT4328012	4000	Losartan vs Lopinavir/Ritonavir vs Hydroxychloroquine	2021–04-01
NCT4330300	2414	Replacing ACE-I and ARB	2021–03-01
NCT4359953	1600	Hydroxychloroquine vs Azithromycin vs Telmisartan	2021–06-01
NCT4356495	1057	Hydroxychloroquine vs Imatinib vs Favipiravir vs Telmisartan	2020–08-15
NCT4335786	651	Valsartan	2021–12
NCT4394117	605	ARB	2021–04-30
NCT4311177	580	Losartan	2021–04-01
NCT4366050	560	Ramipril	2021–04
NCT4329195	554	Discontinuation of RAS blocker therapy	2020–08-09
NCT4364893	500	Suspension of ACE-I and ARB	2020–12-01
NCT4351724	500	Chloroquine/Hydroxychloroquine vs Lopinavir/Ritonavir vs Rivaroxaban vs Thromboprophylaxis vs Candesartan vs non-RAS blocking antihypertensives vs Clazakizumab	2020–12-31
NCT4349410	500	Hydroxychloroquine + Azithromycin vs Hydroxychloroquine + Doxycycline vs Hydroxychloroquine + Clindamycin vs Hydroxychloroquine + Clindamycin + Primaquine vs Remdesivir vs Tocilizumab vs Methylprednisolone vs Interferon-Alpha2B vs Losartan vs Convalescent Serum	2020–11-11
NCT4355936	400	Telmisartan	2020–10-01
NCT4355429	230	Captopril	2020–08
NCT4351581	215	Discontinuation of ACE-I and ARB	2020–12
NCT4353596	208	Stopping/replacing ACE-I and ARB	2022–05-15
NCT4312009	200	Losartan	2021–04-01
NCT4340557	200	Losartan	2020–12-31
NCT4338009	152	Discontinuation of ACE-I and ARB	2020–12-31
NCT4345406	60	Captopril or Enalapril	2029–12-01
NCT4379310	54	ACE-I vs Calcium Channel Blocker	2020–05-08
NCT4335123	50	Losartan	2020–10
NCT4360551	40	Telmisartan	2021–06-30
NCT4357535	17	ARB or ACE-I	2020–05-03
NCT4364984	10	ARB, ACE-I or DRi	2021–08-01

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; DRi, direct renin inhibitors; RAS, renin–angiotensin–aldosterone system.

Summary

The SARS-CoV-2 infection depends on ACE2 which is expressed on host cells. There is no direct evidence for the role of ACE-I or ARBs in the treatment of patients with COVID-19. However, for those patients who are already taking these medications, both the European Society of Cardiology and the American College of Cardiology recommend continuing the treatment. Currently, there is no clear clinical or scientific evidence to justify the discontinuation of ACE-I or ARBs. Individualized treatment decisions should be based on age, clinical condition, and co-morbidities of each patient, weighing the benefits of effective treatment of hypertension or heart failure against the risk of abrupt drug discontinuation. Further multicenter prospective studies are necessary to aid clinicians in the decision-making process.

Disclosure

The authors report no conflicts of interest in this work.